Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in ...

Two drug companies had a bad week. AstraZeneca (AZN) lost 12.06% last week, while Moderna (MRNA) fell by 14.41%. AZN stock ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing ...

CAMBRIDGE, MA / ACCESSWIRE / September 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Taiwan Food & Drug Administration (FDA) has approved an updated formulation of the COVID-19 mRNA ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Moderna (MRNA) shares surged nearly ~15% on Friday to around ~$69 and are now up almost ~42% over the past month. The stock has also crushed the S&P 500 (SP500)'s return of ~7.49%, delivering gains of ...

CAMBRIDGE, MA / ACCESS Newswire / February 10, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) has ...

The Food and Drug Administration's decision, made public on Feb. 10, 2026, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from ...

Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...